Dr. Rejeesh Menon, MD, FACP

Dr. Rejeesh Menon holds an MBBS from T.D. Medical College, University of Kerala, and an MD in Internal Medicine from the University of North Dakota residency program, Fargo. He has been American Board of Internal Medicine (ABIM) certified since 2016 and is a Fellow of the American College of Physicians (FACP). He serves as Clinical Assistant Professor at the Elson S. Floyd College of Medicine, Washington State University.

Dr. Rejeesh Menon is Founder and Chairman of DermaVue Clinics, a seven-clinic network across Kerala and Tamil Nadu, and Medical Director of the SuperHuman Program. He simultaneously practices US hospital medicine as an attending physician at Pullman Regional Hospital, Washington, and a hospitalist at Lourdes Medical Center, Pasco. Consultations in India are delivered through the DermaVue clinic network and nationwide via teleconsultation under the Telemedicine Practice Guidelines 2020.

Internal medicine with a cardiometabolic and obesity-medicine subspecialty interest: GLP-1 receptor agonist therapy (semaglutide, tirzepatide), polycystic ovary syndrome, insulin resistance, type 2 diabetes prevention, and the South Asian thin-fat phenotype that drives cardiometabolic risk at lower BMI thresholds in Indian patients. His prior research at the University of Florida Department of Radiation Oncology focused on intestinal nutrient and electrolyte transport, with eight peer-reviewed publications and six published abstracts.

Indian patients develop insulin resistance, fatty liver, and atherosclerotic disease at lower body weights than Western populations. The Indian consensus thresholds (BMI ≥23 for overweight, ≥25 for obesity, waist 80 cm in women and 90 cm in men) capture this risk; WHO thresholds (25 and 30) systematically underestimate metabolic risk in South Asians. Dr. Menon applies the Indian thresholds across every SuperHuman assessment, in line with ICMR-INDIAB guidance.

Yes. Eight peer-reviewed publications in journals including the American Journal of Physiology-Cell Physiology, Pflügers Archiv, and Health Physics, plus six published abstracts at gastroenterology, FASEB, and ASTRO meetings. He contributed to the development of Enterade, an amino-acid compound for radiation-induced gastrointestinal toxicity, which received the NSBRI SmartCap Award funded by NASA. He serves as a peer reviewer for four journals including the Journal of Gastroenterology and Metabolism.

Yes. SuperHuman Program teleconsultations are delivered under the Telemedicine Practice Guidelines 2020 issued by the Ministry of Health and Family Welfare. The flow is: complete the eligibility quiz, attend a 30-minute video consultation with the SuperHuman team, complete baseline metabolic labs, then receive a personalised GLP-1 protocol where clinically indicated. Cold-chain medication delivery covers most Indian metros and tier-2 cities.

The decision is biological, not commercial. Generic semaglutide (Natco Semanat, Alkem Semasize) from ₹325 per weekly injection is the appropriate starting point for most patients with BMI 23 to 32 and moderate insulin resistance. Ozempic (Novo Nordisk) from ₹1,415 per weekly injection is reserved for patients who need the branded pen device or have specific tolerability requirements. Mounjaro (Eli Lilly tirzepatide) from ₹3,281 per weekly injection is considered for patients with BMI above 32, HbA1c above 6.0 despite metformin, or who have plateaued on maximum-dose semaglutide.

Baseline labs are mandatory: HbA1c, fasting insulin, lipid profile, complete liver function, renal function (eGFR + creatinine), thyroid panel, vitamin D, and vitamin B12. Patients with PCOS receive an extended panel covering SHBG, free testosterone, DHEAS, and 17-hydroxyprogesterone. The SuperHuman team does not initiate GLP-1 therapy on the basis of BMI alone, and recent labs (within 90 days) can be uploaded from any major Indian lab chain.